Conclusion
Our results show that luteolin protects against inflammation-induced dopaminergic neuron loss. Mechanistically, luteolin deactivated TLR4 signaling in microglia, thus improving the inflammatory niche and subsequently attenuating dopaminergic neuronal loss both in vivoand in vitro . Luteolin has limited adverse reactions and displays low toxicity, and thus has broad application prospects as a PD therapeutic.